FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:815 August 21, 2003 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Kilby, J. M. PubMed Citation

To the Editor: In their review article on a new class of drugs that inhibit human immunodeficiency virus type 1 (HIV-1) fusion, Kilby and Eron (May 29 issue)¹ underline the virologic and immunologic benefit of enfuvirtide for drug-resistant HIV-1 infection. In our opinion, this new compound also deserves attention for antiretroviral prophylaxis because it acts before the virus enters the cell, it has activity against resistant strains of HIV when the source of infection is a patient with resistance to multiple anti-HIV drugs, and its subcutaneous route of administration may immediately ensure effective serum levels. The use of enfuvirtide in . . . [Full Text of this Article]

Related Letters:

Enfuvirtide for Prophylaxis against HIV Infection
Cuzin L., Alvarez M., Ferranti S., Menichetti F.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:2169-2170, Nov 27, 2003. Correspondence

This article has been cited by other articles:

• Cuzin, L., Alvarez, M., Ferranti, S., Menichetti, F. (2003). Enfuvirtide for Prophylaxis against HIV Infection. NEJM 349: 2169-2170 [Full Text]